|
Comprehensive Weekly NIH Listings: Current RFAs , Current Parent Announcements
institutes.
-----------------------------------------------------------------
COVID-19 related funding opportunities:
Federal agency grant and funding opportunities
NIH Grants & Funding
Rural Health Information Hub
-----------------------------------------------------------------
NOT-MD-20-022: Competitive and Administrative Supplements for Community Interventions to Reduce the Impact of COVID-19 on Health Disparity and Other Vulnerable Populations
Projects may evaluate existing or ongoing community-based programs or policies (i.e., natural experiments), or prospectively test new or adapted interventions. Multilevel interventions that do not solely target individuals, but also address the upstream determinants that influence individual functioning and health outcomes are strongly encouraged. Projects should be designed to test hypotheses about mechanisms of action that account for an intervention’s effects; mechanisms may operate at any level of analysis.
Key questions include: To what extent do existing interventions slow the spread of COVID-19 in specific populations and geographic hotspots? To what extent do policies, guidelines, and other interventions facilitate adherence and mitigate the multifaceted impacts of COVID-19 on health in populations that experience health disparities and vulnerable groups? Can established models of crisis and disaster response and management be applied to address the needs of health disparity and other vulnerable populations?
-----------------------------------------------------------------
-
NOT-OD-20-021 This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.
-
NOT-OD-20-120 with a similar focus, but shifts the pool of eligible grants for supplementation to individual research awards that include community collaborations or partnerships (or have the capacity to ramp up quickly) to reach underserved and/or COVID-19 vulnerable populations.
-
NOT-OD-20-119 which seeks research to understand the Social, Ethical and Behavioral Implications (SEBI) of COVID-19 testing in these populations.
-
RFA-OD-20-013 which is a U24 Coordination and Data Collection Center (CDCC) as a key component of the consortium.
-----------------------------------------------------------------
National Institute of Allergy and Infectious Diseases (NIAID) is now accepting NEW R01 and R21 proposals in the ongoing effort to investigate SARS-CoV-2. Applications will be handled on an expedited review and award basis to meet the goals of this program. The research goals of the program are to improve understanding of fundamental virology, immunology, and the development of animal models, reagents, and medical countermeasures and to share findings quickly and broadly.
Potential applicants are strongly encouraged to contact Scientific/Research staff before submitting an application to either FOA to determine whether or not the proposed work is within the intended scope of the program and whether requested expedited funding is likely to be available. Deadline: through April 30, 2021.
-----------------------------------------------------------------
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. RADx will support novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. RADx is structured to deliver innovative testing strategies to the public as soon as late summer 2020 and is an accelerated and comprehensive multi-pronged effort by NIH to make SARS-CoV-2 testing readily available to every American.
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. RADx will provide resources to support all phases of the product development pipeline from conceptualization and design to reduction-to-practice, performance evaluation, clinical validation, and scale-up of manufacturing.
Non-profit, academic, and for-profit entities (small and large) are eligible to receive support. Please see the program webpage (www.poctrn.org/radx), press release, and blog post from Francis Collins for details.
-----------------------------------------------------------------
The Connect2HealthFCC Task Force wants to make sure you’re aware that applications are now being accepted for the Federal Communications Commission’s newly-established $200 million COVID-19 Telehealth Program. Applications can be submitted online at https://www.fcc.gov/covid19telehealth. In response to the pandemic and as part of the FCC's implementation of relevant portions of the CARES Act, the new Telehealth Program will help health care providers offer critical connected care services to patients at their homes or mobile locations. The Program affords immediate support to eligible health care providers responding to the pandemic by providing funding for telecommunications services, information services, and devices necessary to deliver critical connected care services.
Quick links are provided below for your convenience:
General Information, including a video explainer: https://www.fcc.gov/covid19telehealth. The Commission will update this webpage periodically.
If you have additional questions related to the Program, e-mail EmergencyTelehealthSupport@fcc.gov.
-----------------------------------------------------------------
Many COVID-19 funding opportunities have already been announced from a variety of sponsoring agencies, and we anticipate more in the coming weeks. In order to help you navigate these opportunities, Research Development has created a new COVID-19 Funding Opportunities section on the OVPR Funding Opportunities website:
https://www.uvm.edu/ovpr/funding-opportunities
We have created a dynamic document in which we will integrate funding opportunities from a variety of sources (federal and non-federal sponsor websites, funding databases, grants.gov, etc.) that are relevant to the UVM research community. We have also provided links to several other resources that you may find useful. We will update this information frequently.
Please note that Sponsored Project Administration (SPA) will continue to host information related to any Sponsor Updates and Guidance related to proposal submission and award management related to COVID-19.
https://www.uvm.edu/spa/covid-19-sponsor-updates-and-uvm-research-guidance
As always, please reach out to the Research Development team if you would like to request assistance with grant development or grantsmanship review of proposals, including those in response to these new COVID-19 funding opportunities.
-----------------------------------------------------------------
NIDA is issuing this Notice of Special Interest (NOSI) NOT-DA-20-047 to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
Background
As people across the U.S. and the rest of the world prepare for what could be a pandemic of the 2019 novel coronavirus, or COVID-19, the research community should be alert to the possibility that it could affect some populations with substance use disorders or HIV particularly hard. Because it attacks the lungs, COVID-19 could be an especially serious threat to those with histories of smoking tobacco or marijuana or of vaping. People who use opioids or methamphetamine may also be vulnerable due to those drugs’ effects on respiratory and pulmonary health and potential effects on immune mechanisms. Likewise, those with HIV may be affected if their immune function is compromised. Additional social and environmental factors associated with drug use may worsen the transmission and treatment of COVID-19, especially among individuals who experience homelessness or incarceration, which is more common among those with a substance use disorder.
Deadlline: March 31, 2021
-----------------------------------------------------------------
NIGMS hopes to stimulate interest in sepsis research in communities that may not have been aware of the challenges of identifying and treating sepsis patients. Sepsis research needs new investigators and new approaches to challenging questions of disease heterogeneity.
NOT GM 19-054 NIGMS Priorities for Sepsis Research and NOT GM 19-057 Strategies to Support Acquisition and Use of Biospecimens for Research on Sepsis in Humans have been released in response to recommendations from an advisory council working group on sepsis. Over the next 3-5 years NIGMS will be optimizing its research grant support of preclinical and clinical sepsis studies to most effectively provide fundamental knowledge of human sepsis. Several specific topics of research interest that involve clinical studies, research organisms, data science and technology development are outlined in NOT GM 19-054. In addition, two areas of low priority are described:
- Studies using rodent models of sepsis unless uniquely well-justified in terms of potential for providing novel insights into human sepsis
- Clinical trials: In general, NIGMS will only consider support of clinical trials that are designed to test strong mechanistic hypotheses and include appropriate patient stratification. NIGMS expects the scientific foundation of all clinical trial applications to be based on data from rigorously designed and controlled human studies that have been published in peer-reviewed literature. NIGMS is unlikely to support large-scale clinical trials unless other NIH institutes/centers or federal agencies provide joint support to optimize trial efficiency, recruitment, and oversight.
Please feel free to reach out to Sarah Dunsmore, the program director for the NIGMS sepsis research portfolio. She will be glad to discuss NIGMS interests in sepsis research and current funding opportunities for sepsis research at NIGMS and other relevant NIH institutes.
-----------------------------------------------------------------
RFA-CA-19-034 Feasibility & Planning Studies for Development of SPOREs to Investigate Cancer Health Disparities (P20)
All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed.
All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees. Due June 19, 2020 and October 18, 2020.
-----------------------------------------------------------------
|